Pawar Law Group Announces Investigation of Securities Claims Against Meridian Bioscience, Inc. - VIVO

NEW YORK, NY / ACCESSWIRE / February 7, 2017 / The Pawar Law Group announces it is investigating potential securities claims on behalf of shareholders of Meridian Bioscience, Inc. (or the "Company") VIVO resulting from allegations that management may have issued materially misleading business information to the investing public.

On January 25, 2017, Meridian announced negative first-quarter 2017 fiscal year ("1Q 2017") financial results, revised its previously issued revenue guidance for the 2017 fiscal year downwards, and announced that the Board of Directors reduced the annual indicated dividend rate. Chief Executive Officer of Meridian, John A. Kraeutler, attributed the negative 1Q 2017 results to revenue declines in Meridian's Americas diagnostic business, Meridian's largest profit driver, across all major product categories, "due to customer buying patterns and general weakness overall." On this news, shares of Meridian fell during intraday trading on January 25, 2017.

Our investigation concerns whether the Company issued false and misleading statements to investors, causing investor losses. If you own Meridian Bioscience shares and wish to protect your investment and recover your losses, please visit http://pawarlawgroup.com/cases/meridian-bioscience-inc/ or contact Vik Pawar at 212-571-0805.

Contact:

Vik Pawar, Esq.
Pawar Law Group
20 Vesey Street, Suite 1210
New York, NY 10007
Tel: (212) 571-0805
Fax: (212) 571-0938
vik@pawarlawgroup.com

SOURCE: Pawar Law Group